氫離子幫浦阻斷劑 (Chinese Wikipedia)
Analysis of information sources in references of the Wikipedia article "氫離子幫浦阻斷劑" in Chinese language version.
refsWebsite
Global rank
Chinese rank
1st place
1st place
11th place
332nd place
5th place
12th place
low place
low place
2,614th place
6,491st place
102nd place
492nd place
7,197th place
9,501st place
low place
low place
18th place
57th place
621st place
1,608th place
choosingwisely.org (Global: 7,197th place; Chinese: 9,501st place)
- Five Things Physicians and Patients Should Question. American Gastroenterological Association. 24 February 2015 [2025-12-28]. （原始内容存档于2015-03-29）.
doi.org (Global: 2nd place; Chinese: 23rd place)
- Fossmark R, Martinsen TC, Waldum HL. Adverse Effects of Proton Pump Inhibitors-Evidence and Plausibility. International Journal of Molecular Sciences. October 2019, 20 (20): 5203. PMC 6829383
. PMID 31640115. doi:10.3390/ijms20205203 . - Sandhu DS, Fass R. Current Trends in the Management of Gastroesophageal Reflux Disease. Gut Liver //www.ncbi.nlm.nih.gov/pmc/articles/PMC5753679
|PMC=缺少标题 (帮助). January 2018, 12 (1): 7–16. PMC 5753679. PMID 28427116. doi:10.5009/gnl16615 . - Garnock-Jones KP. Vonoprazan: first global approval. Drugs. 2015, 75 (4): 439–43. PMID 25744862. S2CID 43293048. doi:10.1007/s40265-015-0368-z.
- World Health Organization. The selection and use of essential medicines, 2025: WHO Model List of Essential Medicines, 24th list. Geneva: World Health Organization. 2025. doi:10.2471/B09474 . hdl:10665/382243 . License: CC BY-NC-SA 3.0 IGO.
- Zajac P, Holbrook A, Super ME, Vogt M. An overview: Current clinical guidelines for the evaluation, diagnosis, treatment, and management of dyspepsia. Osteopathic Family Physician. March–April 2013, 5 (2): 79–85. doi:10.1016/j.osfp.2012.10.005.
- Wang WH, Huang JQ, Zheng GF, Xia HH, Wong WM, Liu XG, Karlberg J, Wong BC. Effects of proton-pump inhibitors on functional dyspepsia: a meta-analysis of randomized placebo-controlled trials. Clinical Gastroenterology and Hepatology. February 2007, 5 (2): 178–85; quiz 140. PMID 17174612. doi:10.1016/j.cgh.2006.09.012.
- Sachar H, Vaidya K, Laine L. Intermittent vs continuous proton pump inhibitor therapy for high-risk bleeding ulcers: a systematic review and meta-analysis. JAMA Internal Medicine. November 2014, 174 (11): 1755–62. PMC 4415726 . PMID 25201154. doi:10.1001/jamainternmed.2014.4056 .
- Yuan Y, Ford AC, Khan KJ, Gisbert JP, Forman D, Leontiadis GI, Tse F, Calvet X, Fallone C, Fischbach L, Oderda G, Bazzoli F, Moayyedi P. Optimum duration of regimens for Helicobacter pylori eradication. The Cochrane Database of Systematic Reviews. December 2013, 2013 (12). PMC 11841770 . PMID 24338763. doi:10.1002/14651858.CD008337.pub2. 已忽略未知参数
|article-number=(帮助) - Sigterman KE, van Pinxteren B, Bonis PA, Lau J, Numans ME. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. The Cochrane Database of Systematic Reviews. May 2013, 2013 (5). PMC 7066537 . PMID 23728637. doi:10.1002/14651858.CD002095.pub5 . 已忽略未知参数
|article-number=(帮助) - Chang AB, Lasserson TJ, Kiljander TO, Connor FL, Gaffney JT, Garske LA. Systematic review and meta-analysis of randomised controlled trials of gastro-oesophageal reflux interventions for chronic cough associated with gastro-oesophageal reflux. BMJ. January 2006, 332 (7532): 11–7. PMC 1325125 . PMID 16330475. doi:10.1136/bmj.38677.559005.55 .
- Singh S, Garg SK, Singh PP, Iyer PG, El-Serag HB. Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett's oesophagus: a systematic review and meta-analysis. Gut. August 2014, 63 (8): 1229–37. PMC 4199831 . PMID 24221456. doi:10.1136/gutjnl-2013-305997.
- Lucendo AJ, Arias Á, Molina-Infante J. Efficacy of Proton Pump Inhibitor Drugs for Inducing Clinical and Histologic Remission in Patients With Symptomatic Esophageal Eosinophilia: A Systematic Review and Meta-Analysis. Clinical Gastroenterology and Hepatology. January 2016, 14 (1): 13–22.e1. PMID 26247167. doi:10.1016/j.cgh.2015.07.041 .
- Alhazzani W, Alenezi F, Jaeschke RZ, Moayyedi P, Cook DJ. Proton pump inhibitors versus histamine 2 receptor antagonists for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis. Critical Care Medicine. March 2013, 41 (3): 693–705. PMID 23318494. S2CID 8138473. doi:10.1097/CCM.0b013e3182758734.
- Epelboym I, Mazeh H. Zollinger-Ellison syndrome: classical considerations and current controversies. The Oncologist. January 2014, 19 (1): 44–50. PMC 3903066 . PMID 24319020. doi:10.1634/theoncologist.2013-0369.
- Kahrilas PJ, Shaheen NJ, Vaezi MF, Hiltz SW, Black E, Modlin IM, Johnson SP, Allen J, Brill JV. American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. Gastroenterology. October 2008, 135 (4): 1383–1391, 1391.e1–5. PMID 18789939. doi:10.1053/j.gastro.2008.08.045 .
- Xie Y, Bowe B, Yan Y, Xian H, Li T, Al-Aly Z. Estimates of all cause mortality and cause specific mortality associated with proton pump inhibitors among US veterans: cohort study. BMJ (Washington University School of Medicine). May 2019, 365 [2025-12-28]. PMC 6538974 . PMID 31147311. doi:10.1136/bmj.l1580. （原始内容存档于2019-07-18）.
Taking PPIs is associated with a small excess of cause specific mortality including death due to cardiovascular disease, chronic kidney disease, and upper gastrointestinal cancer. The burden was also observed in patients without an indication for PPI use.
已忽略未知参数|article-number=(帮助); 温哥华格式错误 (帮助) - Cooper BT, Chapman W, Neumann CS, Gearty JC. Continuous treatment of Barrett's oesophagus patients with proton pump inhibitors up to 13 years: observations on regression and cancer incidence. Alimentary Pharmacology & Therapeutics. March 2006, 23 (6): 727–33. PMID 16556174. S2CID 6969621. doi:10.1111/j.1365-2036.2006.02825.x .
- Persistent throat symptoms should not be treated with pills that reduce stomach acid. NIHR Evidence (summary). 2022-01-12 [2022-07-06]. S2CID 245960803. doi:10.3310/alert_48810. （原始内容存档于2025-09-18）.
- Wilson JA, Stocken DD, Watson GC, Fouweather T, McGlashan J, MacKenzie K, Carding P, Karagama Y, Harries M, Ball S, Khwaja S, Costello D, Wood R, Lecouturier J, O'Hara J. Lansoprazole for persistent throat symptoms in secondary care: the TOPPITS RCT. Health Technology Assessment. January 2021, 25 (3): 1–118. ISSN 2046-4924. PMC 7869007 . PMID 33492208. S2CID 231702049. doi:10.3310/hta25030 .
- Canadian Cardiovascular Society and Choosing Wisely Canada: The Road to Creating a List of Five Things Physicians and Patients Should Question. Canadian Journal of Cardiology. August 2014, 30 (8): 949–955. ISSN 0828-282X. doi:10.1016/j.cjca.2014.06.010.
- Simpson, Ian J; Marshall, Mark R; Pilmore, Helen; Manley, Paul; Williams, Laurie; Thein, Hla; Voss, David. Proton pump inhibitors and acute interstitial nephritis: Report and analysis of 15 cases. Nephrology. 2006-10, 11 (5): 381-385 [2025-01-24]. ISSN 1320-5358. doi:10.1111/j.1440-1797.2006.00651.x. （原始内容存档于2023-11-13） （英语）.
- Zhang, M. L.; Fan, Y. X.; Meng, R.; Cai, W. K.; Yin, S. J.; Zhou, T.; Huang, Y. H.; Wang, P.; Jiang, F. F.; Yang, M.; He, G. H. Proton Pump Inhibitors and Cancer Risk: An Umbrella Review and Meta-analysis of Observational Studies. American Journal of Clinical Oncology. 2022, 45 (11): 475–485. PMID 36255347. S2CID 252970194. doi:10.1097/COC.0000000000000949.
- Lambert AA, Lam JO, Paik JJ, Ugarte-Gil C, Drummond MB, Crowell TA. Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis. PLOS ONE. 2015, 10 (6). Bibcode:2015PLoSO..1028004L. PMC 4456166 . PMID 26042842. doi:10.1371/journal.pone.0128004 . 已忽略未知参数
|article-number=(帮助) - Eom CS, Jeon CY, Lim JW, Cho EG, Park SM, Lee KS. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ. February 2011, 183 (3): 310–9. PMC 3042441 . PMID 21173070. doi:10.1503/cmaj.092129.
- Hussain S, Singh A, Habib A, Najmi AK. Proton pump inhibitors use and risk of chronic kidney disease: Evidence-based meta-analysis of observational studies. Clinical Epidemiology and Global Health. 2019, 7: 46–52. doi:10.1016/j.cegh.2017.12.008 .
- Lazarus B, Chen Y, Wilson FP, Sang Y, Chang AR, Coresh J, Grams ME. Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease. JAMA Internal Medicine (American Medical Association (AMA)). February 2016, 176 (2): 238–46. PMC 4772730 . PMID 26752337. doi:10.1001/jamainternmed.2015.7193.
- Xie Y, Bowe B, Li T, Xian H, Yan Y, Al-Aly Z. Long-term kidney outcomes among users of proton pump inhibitors without intervening acute kidney injury. Kidney International (Elsevier BV). June 2017, 91 (6): 1482–1494. PMID 28237709. doi:10.1016/j.kint.2016.12.021 .
- Moledina DG, Perazella MA. Proton Pump Inhibitors and CKD. Journal of the American Society of Nephrology (American Society of Nephrology (ASN)). October 2016, 27 (10): 2926–2928. PMC 5042680 . PMID 27080978. doi:10.1681/asn.2016020192.
- Xie Y, Bowe B, Li T, Xian H, Balasubramanian S, Al-Aly Z. Proton Pump Inhibitors and Risk of Incident CKD and Progression to ESRD. Journal of the American Society of Nephrology (American Society of Nephrology (ASN)). October 2016, 27 (10): 3153–3163. PMC 5042677 . PMID 27080976. doi:10.1681/asn.2015121377.
- Salman Hussain, Ambrish Singh et al. No association between proton pump inhibitors use and risk of dementia: Evidence from a meta-analysis. J Gastroenterol Hepatol. https://doi.org/10.1111/jgh.14789 （页面存档备份，存于互联网档案馆）
- Freedberg DE, Kim LS, Yang YX. The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association. Gastroenterology. March 2017, 152 (4): 706–715. PMID 28257716. doi:10.1053/j.gastro.2017.01.031.
Conclusions:Baseline differences between PPI users and non-users make it challenging to study potential PPI adverse effects retrospectively. Despite a large number of studies, the overall quality of evidence for PPI adverse effects is low to very low. When PPIs are appropriately prescribed, their benefits are likely to outweigh their risks. When PPIs are inappropriately prescribed, modest risks become important because there is no potential benefit. There is currently insufficient evidence to recommend specific strategies for mitigating PPI adverse effects.
- Schnoll-Sussman F, Katz PO. Clinical Implications of Emerging Data on the Safety of Proton Pump Inhibitors. Current Treatment Options in Gastroenterology. March 2017, 15 (1): 1–9. PMID 28130652. S2CID 24718665. doi:10.1007/s11938-017-0115-5.
The methodology of these studies allows us to find an association with these events but does not provide us with sufficient evidence to determine causality. In general, the findings of the available studies do not fit with our clinical experience nor is the magnitude of the association sufficient to result in a major change in our practice. Nevertheless, the recent literature has resulted in our careful reevaluation of PPI use across both FDA indications and in general.
- Singh A, Hussain S, Jha R, Jayraj AS, Klugar M, Antony B. Proton pump inhibitor use and the risk of hepatocellular carcinoma: A systematic review of pharmacoepidemiological data. Journal of Evidence-Based Medicine. December 2021, 14 (4): 278–280. PMID 34643998. S2CID 238746424. doi:10.1111/jebm.12456.
- Vaezi MF, Yang YX, Howden CW. Complications of Proton Pump Inhibitor Therapy. Gastroenterology. July 2017, 153 (1): 35–48. PMID 28528705. doi:10.1053/j.gastro.2017.04.047 .
In turn, this has caused unnecessary concern among patients and prescribers. The benefits of PPI therapy for appropriate indications need to be considered, along with the likelihood of the proposed risks. Patients with a proven indication for a PPI should continue to receive it in the lowest effective dose. PPI dose escalation and continued chronic therapy in those unresponsive to initial empiric therapy is discouraged.
- Kia L, Kahrilas PJ. Therapy: Risks associated with chronic PPI use - signal or noise?. Nature Reviews. Gastroenterology & Hepatology. May 2016, 13 (5): 253–4 [2025-12-28]. PMID 27006255. S2CID 19207074. doi:10.1038/nrgastro.2016.44. （原始内容存档于2019-06-20）.
- Sachs G, Shin JM, Howden CW. Review article: the clinical pharmacology of proton pump inhibitors. Alimentary Pharmacology & Therapeutics. June 2006, 23 (Suppl 2): 2–8. PMID 16700898. S2CID 30413194. doi:10.1111/j.1365-2036.2006.02943.x .
- Kim HK, Park SH, Cheung DY, Cho YS, Kim JI, Kim SS, Chae HS, Kim JK, Chung IS. Clinical trial: inhibitory effect of revaprazan on gastric acid secretion in healthy male subjects. Journal of Gastroenterology and Hepatology. October 2010, 25 (10): 1618–25. PMID 20880169. S2CID 41932174. doi:10.1111/j.1440-1746.2010.06408.x.
- Strand DS, Kim D, Peura DA. 25 Years of Proton Pump Inhibitors: A Comprehensive Review. Gut and Liver. January 2017, 11 (1): 27–37. PMC 5221858 . PMID 27840364. doi:10.5009/gnl15502.
fda.gov (Global: 447th place; Chinese: 581st place)
- FDA Drug Safety Communication: Possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors. U.S. Food and Drug Administration (FDA). 2011-03-23 [2015-08-23]. （原始内容存档于2020-03-20）.
- Low magnesium levels can be associated with long-term use of PPIs. U.S. Food and Drug Administration (FDA). 2009-11-17 [2020-02-23]. （原始内容存档于2019-10-24）.
globenewswire.com (Global: 2,614th place; Chinese: 6,491st place)
- Phathom Pharmaceuticals Announces Commercial Availability of Voquezna (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated Heartburn. GlobeNewswire (新闻稿). Phathom Pharmaceuticals. 2023-11-28 [2024-01-26].
gov.bc.ca (Global: 2,476th place; Chinese: 4,009th place)
www2.gov.bc.ca
- Proton Pump Inhibitors in Primary Care (PDF). Province of British Columbia. January 2015 [2025-12-28]. （原始内容存档 (PDF)于2020-12-23）.
handle.net (Global: 102nd place; Chinese: 492nd place)
hdl.handle.net
- World Health Organization. The selection and use of essential medicines, 2025: WHO Model List of Essential Medicines, 24th list. Geneva: World Health Organization. 2025. doi:10.2471/B09474 . hdl:10665/382243 . License: CC BY-NC-SA 3.0 IGO.
harvard.edu (Global: 18th place; Chinese: 57th place)
ui.adsabs.harvard.edu
- Lambert AA, Lam JO, Paik JJ, Ugarte-Gil C, Drummond MB, Crowell TA. Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis. PLOS ONE. 2015, 10 (6). Bibcode:2015PLoSO..1028004L. PMC 4456166 . PMID 26042842. doi:10.1371/journal.pone.0128004 . 已忽略未知参数
|article-number=(帮助)
natap.org (Global: low place; Chinese: low place)
- Evidence That Proton-Pump Inhibitor Therapy Induces the Symptoms it Is Used to Treat EDITORIAL. www.natap.org. [2025-01-24]. （原始内容存档于2025-01-09）.
nih.gov (Global: 4th place; Chinese: 5th place)
ncbi.nlm.nih.gov
- Fossmark R, Martinsen TC, Waldum HL. Adverse Effects of Proton Pump Inhibitors-Evidence and Plausibility. International Journal of Molecular Sciences. October 2019, 20 (20): 5203. PMC 6829383 . PMID 31640115. doi:10.3390/ijms20205203 .
- Sandhu DS, Fass R. Current Trends in the Management of Gastroesophageal Reflux Disease. Gut Liver //www.ncbi.nlm.nih.gov/pmc/articles/PMC5753679
|PMC=缺少标题 (帮助). January 2018, 12 (1): 7–16. PMC 5753679. PMID 28427116. doi:10.5009/gnl16615 . - Garnock-Jones KP. Vonoprazan: first global approval. Drugs. 2015, 75 (4): 439–43. PMID 25744862. S2CID 43293048. doi:10.1007/s40265-015-0368-z.
- Wang WH, Huang JQ, Zheng GF, Xia HH, Wong WM, Liu XG, Karlberg J, Wong BC. Effects of proton-pump inhibitors on functional dyspepsia: a meta-analysis of randomized placebo-controlled trials. Clinical Gastroenterology and Hepatology. February 2007, 5 (2): 178–85; quiz 140. PMID 17174612. doi:10.1016/j.cgh.2006.09.012.
- Sachar H, Vaidya K, Laine L. Intermittent vs continuous proton pump inhibitor therapy for high-risk bleeding ulcers: a systematic review and meta-analysis. JAMA Internal Medicine. November 2014, 174 (11): 1755–62. PMC 4415726 . PMID 25201154. doi:10.1001/jamainternmed.2014.4056 .
- Yuan Y, Ford AC, Khan KJ, Gisbert JP, Forman D, Leontiadis GI, Tse F, Calvet X, Fallone C, Fischbach L, Oderda G, Bazzoli F, Moayyedi P. Optimum duration of regimens for Helicobacter pylori eradication. The Cochrane Database of Systematic Reviews. December 2013, 2013 (12). PMC 11841770 . PMID 24338763. doi:10.1002/14651858.CD008337.pub2. 已忽略未知参数
|article-number=(帮助) - Sigterman KE, van Pinxteren B, Bonis PA, Lau J, Numans ME. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. The Cochrane Database of Systematic Reviews. May 2013, 2013 (5). PMC 7066537 . PMID 23728637. doi:10.1002/14651858.CD002095.pub5 . 已忽略未知参数
|article-number=(帮助) - Qadeer MA, Phillips CO, Lopez AR, Steward DL, Noordzij JP, Wo JM, Suurna M, Havas T, Howden CW, Vaezi MF. Proton pump inhibitor therapy for suspected GERD-related chronic laryngitis: a meta-analysis of randomized controlled trials. The American Journal of Gastroenterology. November 2006, 101 (11): 2646–54. PMID 17037995.
- Chang AB, Lasserson TJ, Kiljander TO, Connor FL, Gaffney JT, Garske LA. Systematic review and meta-analysis of randomised controlled trials of gastro-oesophageal reflux interventions for chronic cough associated with gastro-oesophageal reflux. BMJ. January 2006, 332 (7532): 11–7. PMC 1325125 . PMID 16330475. doi:10.1136/bmj.38677.559005.55 .
- Singh S, Garg SK, Singh PP, Iyer PG, El-Serag HB. Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett's oesophagus: a systematic review and meta-analysis. Gut. August 2014, 63 (8): 1229–37. PMC 4199831 . PMID 24221456. doi:10.1136/gutjnl-2013-305997.
- Lucendo AJ, Arias Á, Molina-Infante J. Efficacy of Proton Pump Inhibitor Drugs for Inducing Clinical and Histologic Remission in Patients With Symptomatic Esophageal Eosinophilia: A Systematic Review and Meta-Analysis. Clinical Gastroenterology and Hepatology. January 2016, 14 (1): 13–22.e1. PMID 26247167. doi:10.1016/j.cgh.2015.07.041 .
- Alhazzani W, Alenezi F, Jaeschke RZ, Moayyedi P, Cook DJ. Proton pump inhibitors versus histamine 2 receptor antagonists for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis. Critical Care Medicine. March 2013, 41 (3): 693–705. PMID 23318494. S2CID 8138473. doi:10.1097/CCM.0b013e3182758734.
- Epelboym I, Mazeh H. Zollinger-Ellison syndrome: classical considerations and current controversies. The Oncologist. January 2014, 19 (1): 44–50. PMC 3903066 . PMID 24319020. doi:10.1634/theoncologist.2013-0369.
- Kahrilas PJ, Shaheen NJ, Vaezi MF, Hiltz SW, Black E, Modlin IM, Johnson SP, Allen J, Brill JV. American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. Gastroenterology. October 2008, 135 (4): 1383–1391, 1391.e1–5. PMID 18789939. doi:10.1053/j.gastro.2008.08.045 .
- Xie Y, Bowe B, Yan Y, Xian H, Li T, Al-Aly Z. Estimates of all cause mortality and cause specific mortality associated with proton pump inhibitors among US veterans: cohort study. BMJ (Washington University School of Medicine). May 2019, 365 [2025-12-28]. PMC 6538974 . PMID 31147311. doi:10.1136/bmj.l1580. （原始内容存档于2019-07-18）.
Taking PPIs is associated with a small excess of cause specific mortality including death due to cardiovascular disease, chronic kidney disease, and upper gastrointestinal cancer. The burden was also observed in patients without an indication for PPI use.
已忽略未知参数|article-number=(帮助); 温哥华格式错误 (帮助) - Cooper BT, Chapman W, Neumann CS, Gearty JC. Continuous treatment of Barrett's oesophagus patients with proton pump inhibitors up to 13 years: observations on regression and cancer incidence. Alimentary Pharmacology & Therapeutics. March 2006, 23 (6): 727–33. PMID 16556174. S2CID 6969621. doi:10.1111/j.1365-2036.2006.02825.x .
- Wilson JA, Stocken DD, Watson GC, Fouweather T, McGlashan J, MacKenzie K, Carding P, Karagama Y, Harries M, Ball S, Khwaja S, Costello D, Wood R, Lecouturier J, O'Hara J. Lansoprazole for persistent throat symptoms in secondary care: the TOPPITS RCT. Health Technology Assessment. January 2021, 25 (3): 1–118. ISSN 2046-4924. PMC 7869007 . PMID 33492208. S2CID 231702049. doi:10.3310/hta25030 .
- Farrell B, Pottie K, Thompson W, Boghossian T, Pizzola L, Rashid FJ, Rojas-Fernandez C, Walsh K, Welch V, Moayyedi P. Deprescribing proton pump inhibitors: Evidence-based clinical practice guideline. Canadian Family Physician. May 2017, 63 (5): 354–364. PMC 5429051 . PMID 28500192.
- Zhang, M. L.; Fan, Y. X.; Meng, R.; Cai, W. K.; Yin, S. J.; Zhou, T.; Huang, Y. H.; Wang, P.; Jiang, F. F.; Yang, M.; He, G. H. Proton Pump Inhibitors and Cancer Risk: An Umbrella Review and Meta-analysis of Observational Studies. American Journal of Clinical Oncology. 2022, 45 (11): 475–485. PMID 36255347. S2CID 252970194. doi:10.1097/COC.0000000000000949.
- Lambert AA, Lam JO, Paik JJ, Ugarte-Gil C, Drummond MB, Crowell TA. Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis. PLOS ONE. 2015, 10 (6). Bibcode:2015PLoSO..1028004L. PMC 4456166 . PMID 26042842. doi:10.1371/journal.pone.0128004 . 已忽略未知参数
|article-number=(帮助) - Eom CS, Jeon CY, Lim JW, Cho EG, Park SM, Lee KS. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ. February 2011, 183 (3): 310–9. PMC 3042441 . PMID 21173070. doi:10.1503/cmaj.092129.
- Lazarus B, Chen Y, Wilson FP, Sang Y, Chang AR, Coresh J, Grams ME. Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease. JAMA Internal Medicine (American Medical Association (AMA)). February 2016, 176 (2): 238–46. PMC 4772730 . PMID 26752337. doi:10.1001/jamainternmed.2015.7193.
- Xie Y, Bowe B, Li T, Xian H, Yan Y, Al-Aly Z. Long-term kidney outcomes among users of proton pump inhibitors without intervening acute kidney injury. Kidney International (Elsevier BV). June 2017, 91 (6): 1482–1494. PMID 28237709. doi:10.1016/j.kint.2016.12.021 .
- Moledina DG, Perazella MA. Proton Pump Inhibitors and CKD. Journal of the American Society of Nephrology (American Society of Nephrology (ASN)). October 2016, 27 (10): 2926–2928. PMC 5042680 . PMID 27080978. doi:10.1681/asn.2016020192.
- Xie Y, Bowe B, Li T, Xian H, Balasubramanian S, Al-Aly Z. Proton Pump Inhibitors and Risk of Incident CKD and Progression to ESRD. Journal of the American Society of Nephrology (American Society of Nephrology (ASN)). October 2016, 27 (10): 3153–3163. PMC 5042677 . PMID 27080976. doi:10.1681/asn.2015121377.
- Freedberg DE, Kim LS, Yang YX. The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association. Gastroenterology. March 2017, 152 (4): 706–715. PMID 28257716. doi:10.1053/j.gastro.2017.01.031.
Conclusions:Baseline differences between PPI users and non-users make it challenging to study potential PPI adverse effects retrospectively. Despite a large number of studies, the overall quality of evidence for PPI adverse effects is low to very low. When PPIs are appropriately prescribed, their benefits are likely to outweigh their risks. When PPIs are inappropriately prescribed, modest risks become important because there is no potential benefit. There is currently insufficient evidence to recommend specific strategies for mitigating PPI adverse effects.
- Schnoll-Sussman F, Katz PO. Clinical Implications of Emerging Data on the Safety of Proton Pump Inhibitors. Current Treatment Options in Gastroenterology. March 2017, 15 (1): 1–9. PMID 28130652. S2CID 24718665. doi:10.1007/s11938-017-0115-5.
The methodology of these studies allows us to find an association with these events but does not provide us with sufficient evidence to determine causality. In general, the findings of the available studies do not fit with our clinical experience nor is the magnitude of the association sufficient to result in a major change in our practice. Nevertheless, the recent literature has resulted in our careful reevaluation of PPI use across both FDA indications and in general.
- Singh A, Hussain S, Jha R, Jayraj AS, Klugar M, Antony B. Proton pump inhibitor use and the risk of hepatocellular carcinoma: A systematic review of pharmacoepidemiological data. Journal of Evidence-Based Medicine. December 2021, 14 (4): 278–280. PMID 34643998. S2CID 238746424. doi:10.1111/jebm.12456.
- Vaezi MF, Yang YX, Howden CW. Complications of Proton Pump Inhibitor Therapy. Gastroenterology. July 2017, 153 (1): 35–48. PMID 28528705. doi:10.1053/j.gastro.2017.04.047 .
In turn, this has caused unnecessary concern among patients and prescribers. The benefits of PPI therapy for appropriate indications need to be considered, along with the likelihood of the proposed risks. Patients with a proven indication for a PPI should continue to receive it in the lowest effective dose. PPI dose escalation and continued chronic therapy in those unresponsive to initial empiric therapy is discouraged.
- Kia L, Kahrilas PJ. Therapy: Risks associated with chronic PPI use - signal or noise?. Nature Reviews. Gastroenterology & Hepatology. May 2016, 13 (5): 253–4 [2025-12-28]. PMID 27006255. S2CID 19207074. doi:10.1038/nrgastro.2016.44. （原始内容存档于2019-06-20）.
- Sachs G, Shin JM, Howden CW. Review article: the clinical pharmacology of proton pump inhibitors. Alimentary Pharmacology & Therapeutics. June 2006, 23 (Suppl 2): 2–8. PMID 16700898. S2CID 30413194. doi:10.1111/j.1365-2036.2006.02943.x .
- Kim HK, Park SH, Cheung DY, Cho YS, Kim JI, Kim SS, Chae HS, Kim JK, Chung IS. Clinical trial: inhibitory effect of revaprazan on gastric acid secretion in healthy male subjects. Journal of Gastroenterology and Hepatology. October 2010, 25 (10): 1618–25. PMID 20880169. S2CID 41932174. doi:10.1111/j.1440-1746.2010.06408.x.
- Dean L. Comparing Proton Pump Inhibitors. PubMed Clinical Q&A. National Center for Biotechnology Information (US). October 2010 [2025-12-28]. （原始内容存档于2023-12-14）.
- Strand DS, Kim D, Peura DA. 25 Years of Proton Pump Inhibitors: A Comprehensive Review. Gut and Liver. January 2017, 11 (1): 27–37. PMC 5221858 . PMID 27840364. doi:10.5009/gnl15502.
nihr.ac.uk (Global: low place; Chinese: low place)
evidence.nihr.ac.uk
- Persistent throat symptoms should not be treated with pills that reduce stomach acid. NIHR Evidence (summary). 2022-01-12 [2022-07-06]. S2CID 245960803. doi:10.3310/alert_48810. （原始内容存档于2025-09-18）.
rosminzdrav.ru (Global: low place; Chinese: low place)
grls.rosminzdrav.ru
- Russian State Register of Medicines. Vocinti (vonoprazan) Film-Coated Tablets. Full Prescribing Information. grls.rosminzdrav.ru. Takeda Pharmaceutical Company Limited. [2023-02-18]. （原始内容存档于2023-02-18） （Russian）.
semanticscholar.org (Global: 11th place; Chinese: 332nd place)
api.semanticscholar.org
- Garnock-Jones KP. Vonoprazan: first global approval. Drugs. 2015, 75 (4): 439–43. PMID 25744862. S2CID 43293048. doi:10.1007/s40265-015-0368-z.
- Alhazzani W, Alenezi F, Jaeschke RZ, Moayyedi P, Cook DJ. Proton pump inhibitors versus histamine 2 receptor antagonists for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis. Critical Care Medicine. March 2013, 41 (3): 693–705. PMID 23318494. S2CID 8138473. doi:10.1097/CCM.0b013e3182758734.
- Cooper BT, Chapman W, Neumann CS, Gearty JC. Continuous treatment of Barrett's oesophagus patients with proton pump inhibitors up to 13 years: observations on regression and cancer incidence. Alimentary Pharmacology & Therapeutics. March 2006, 23 (6): 727–33. PMID 16556174. S2CID 6969621. doi:10.1111/j.1365-2036.2006.02825.x .
- Persistent throat symptoms should not be treated with pills that reduce stomach acid. NIHR Evidence (summary). 2022-01-12 [2022-07-06]. S2CID 245960803. doi:10.3310/alert_48810. （原始内容存档于2025-09-18）.
- Wilson JA, Stocken DD, Watson GC, Fouweather T, McGlashan J, MacKenzie K, Carding P, Karagama Y, Harries M, Ball S, Khwaja S, Costello D, Wood R, Lecouturier J, O'Hara J. Lansoprazole for persistent throat symptoms in secondary care: the TOPPITS RCT. Health Technology Assessment. January 2021, 25 (3): 1–118. ISSN 2046-4924. PMC 7869007 . PMID 33492208. S2CID 231702049. doi:10.3310/hta25030 .
- Zhang, M. L.; Fan, Y. X.; Meng, R.; Cai, W. K.; Yin, S. J.; Zhou, T.; Huang, Y. H.; Wang, P.; Jiang, F. F.; Yang, M.; He, G. H. Proton Pump Inhibitors and Cancer Risk: An Umbrella Review and Meta-analysis of Observational Studies. American Journal of Clinical Oncology. 2022, 45 (11): 475–485. PMID 36255347. S2CID 252970194. doi:10.1097/COC.0000000000000949.
- Schnoll-Sussman F, Katz PO. Clinical Implications of Emerging Data on the Safety of Proton Pump Inhibitors. Current Treatment Options in Gastroenterology. March 2017, 15 (1): 1–9. PMID 28130652. S2CID 24718665. doi:10.1007/s11938-017-0115-5.
The methodology of these studies allows us to find an association with these events but does not provide us with sufficient evidence to determine causality. In general, the findings of the available studies do not fit with our clinical experience nor is the magnitude of the association sufficient to result in a major change in our practice. Nevertheless, the recent literature has resulted in our careful reevaluation of PPI use across both FDA indications and in general.
- Singh A, Hussain S, Jha R, Jayraj AS, Klugar M, Antony B. Proton pump inhibitor use and the risk of hepatocellular carcinoma: A systematic review of pharmacoepidemiological data. Journal of Evidence-Based Medicine. December 2021, 14 (4): 278–280. PMID 34643998. S2CID 238746424. doi:10.1111/jebm.12456.
- Kia L, Kahrilas PJ. Therapy: Risks associated with chronic PPI use - signal or noise?. Nature Reviews. Gastroenterology & Hepatology. May 2016, 13 (5): 253–4 [2025-12-28]. PMID 27006255. S2CID 19207074. doi:10.1038/nrgastro.2016.44. （原始内容存档于2019-06-20）.
- Sachs G, Shin JM, Howden CW. Review article: the clinical pharmacology of proton pump inhibitors. Alimentary Pharmacology & Therapeutics. June 2006, 23 (Suppl 2): 2–8. PMID 16700898. S2CID 30413194. doi:10.1111/j.1365-2036.2006.02943.x .
- Kim HK, Park SH, Cheung DY, Cho YS, Kim JI, Kim SS, Chae HS, Kim JK, Chung IS. Clinical trial: inhibitory effect of revaprazan on gastric acid secretion in healthy male subjects. Journal of Gastroenterology and Hepatology. October 2010, 25 (10): 1618–25. PMID 20880169. S2CID 41932174. doi:10.1111/j.1440-1746.2010.06408.x.
ubc.ca (Global: 1,997th place; Chinese: 1,771st place)
ti.ubc.ca
- [99] Comparative effectiveness of proton pump inhibitors. Therapeutics Letter. 2016-06-28 [2016-07-14]. ISSN 2369-8691. （原始内容存档于2016-07-09）.
udn.com (Global: 392nd place; Chinese: 10th place)
health.udn.com
- UDN-PPI會致死??. [2017-07-26]. （原始内容存档于2017-07-25）.
web.archive.org (Global: 1st place; Chinese: 1st place)
- [99] Comparative effectiveness of proton pump inhibitors. Therapeutics Letter. 2016-06-28 [2016-07-14]. ISSN 2369-8691. （原始内容存档于2016-07-09）.
- Russian State Register of Medicines. Vocinti (vonoprazan) Film-Coated Tablets. Full Prescribing Information. grls.rosminzdrav.ru. Takeda Pharmaceutical Company Limited. [2023-02-18]. （原始内容存档于2023-02-18） （Russian）.
- Five Things Physicians and Patients Should Question. American Gastroenterological Association. 24 February 2015 [2025-12-28]. （原始内容存档于2015-03-29）.
- Xie Y, Bowe B, Yan Y, Xian H, Li T, Al-Aly Z. Estimates of all cause mortality and cause specific mortality associated with proton pump inhibitors among US veterans: cohort study. BMJ (Washington University School of Medicine). May 2019, 365 [2025-12-28]. PMC 6538974 . PMID 31147311. doi:10.1136/bmj.l1580. （原始内容存档于2019-07-18）.
Taking PPIs is associated with a small excess of cause specific mortality including death due to cardiovascular disease, chronic kidney disease, and upper gastrointestinal cancer. The burden was also observed in patients without an indication for PPI use.
已忽略未知参数|article-number=(帮助); 温哥华格式错误 (帮助) - FDA Drug Safety Communication: Possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors. U.S. Food and Drug Administration (FDA). 2011-03-23 [2015-08-23]. （原始内容存档于2020-03-20）.
- Low magnesium levels can be associated with long-term use of PPIs. U.S. Food and Drug Administration (FDA). 2009-11-17 [2020-02-23]. （原始内容存档于2019-10-24）.
- Persistent throat symptoms should not be treated with pills that reduce stomach acid. NIHR Evidence (summary). 2022-01-12 [2022-07-06]. S2CID 245960803. doi:10.3310/alert_48810. （原始内容存档于2025-09-18）.
- Evidence That Proton-Pump Inhibitor Therapy Induces the Symptoms it Is Used to Treat EDITORIAL. www.natap.org. [2025-01-24]. （原始内容存档于2025-01-09）.
- Beck, Melinda. Tired And Confused? Vitamin B12 May Be Low. Wall Street Journal. 2011-01-17 [2025-01-24]. ISSN 0099-9660. （原始内容存档于2013-05-13） （美国英语）.
- Simpson, Ian J; Marshall, Mark R; Pilmore, Helen; Manley, Paul; Williams, Laurie; Thein, Hla; Voss, David. Proton pump inhibitors and acute interstitial nephritis: Report and analysis of 15 cases. Nephrology. 2006-10, 11 (5): 381-385 [2025-01-24]. ISSN 1320-5358. doi:10.1111/j.1440-1797.2006.00651.x. （原始内容存档于2023-11-13） （英语）.
- UDN-PPI會致死??. [2017-07-26]. （原始内容存档于2017-07-25）.
- Salman Hussain, Ambrish Singh et al. No association between proton pump inhibitors use and risk of dementia: Evidence from a meta-analysis. J Gastroenterol Hepatol. https://doi.org/10.1111/jgh.14789 （页面存档备份，存于互联网档案馆）
- Kia L, Kahrilas PJ. Therapy: Risks associated with chronic PPI use - signal or noise?. Nature Reviews. Gastroenterology & Hepatology. May 2016, 13 (5): 253–4 [2025-12-28]. PMID 27006255. S2CID 19207074. doi:10.1038/nrgastro.2016.44. （原始内容存档于2019-06-20）.
- Proton Pump Inhibitors in Primary Care (PDF). Province of British Columbia. January 2015 [2025-12-28]. （原始内容存档 (PDF)于2020-12-23）.
- Dean L. Comparing Proton Pump Inhibitors. PubMed Clinical Q&A. National Center for Biotechnology Information (US). October 2010 [2025-12-28]. （原始内容存档于2023-12-14）.
wiley.com (Global: 222nd place; Chinese: 216th place)
onlinelibrary.wiley.com
- Simpson, Ian J; Marshall, Mark R; Pilmore, Helen; Manley, Paul; Williams, Laurie; Thein, Hla; Voss, David. Proton pump inhibitors and acute interstitial nephritis: Report and analysis of 15 cases. Nephrology. 2006-10, 11 (5): 381-385 [2025-01-24]. ISSN 1320-5358. doi:10.1111/j.1440-1797.2006.00651.x. （原始内容存档于2023-11-13） （英语）.
worldcat.org (Global: 5th place; Chinese: 12th place)
- [99] Comparative effectiveness of proton pump inhibitors. Therapeutics Letter. 2016-06-28 [2016-07-14]. ISSN 2369-8691. （原始内容存档于2016-07-09）.
- Wilson JA, Stocken DD, Watson GC, Fouweather T, McGlashan J, MacKenzie K, Carding P, Karagama Y, Harries M, Ball S, Khwaja S, Costello D, Wood R, Lecouturier J, O'Hara J. Lansoprazole for persistent throat symptoms in secondary care: the TOPPITS RCT. Health Technology Assessment. January 2021, 25 (3): 1–118. ISSN 2046-4924. PMC 7869007 . PMID 33492208. S2CID 231702049. doi:10.3310/hta25030 .
- Canadian Cardiovascular Society and Choosing Wisely Canada: The Road to Creating a List of Five Things Physicians and Patients Should Question. Canadian Journal of Cardiology. August 2014, 30 (8): 949–955. ISSN 0828-282X. doi:10.1016/j.cjca.2014.06.010.
- Beck, Melinda. Tired And Confused? Vitamin B12 May Be Low. Wall Street Journal. 2011-01-17 [2025-01-24]. ISSN 0099-9660. （原始内容存档于2013-05-13） （美国英语）.
- Simpson, Ian J; Marshall, Mark R; Pilmore, Helen; Manley, Paul; Williams, Laurie; Thein, Hla; Voss, David. Proton pump inhibitors and acute interstitial nephritis: Report and analysis of 15 cases. Nephrology. 2006-10, 11 (5): 381-385 [2025-01-24]. ISSN 1320-5358. doi:10.1111/j.1440-1797.2006.00651.x. （原始内容存档于2023-11-13） （英语）.
wsj.com (Global: 79th place; Chinese: 143rd place)
- Beck, Melinda. Tired And Confused? Vitamin B12 May Be Low. Wall Street Journal. 2011-01-17 [2025-01-24]. ISSN 0099-9660. （原始内容存档于2013-05-13） （美国英语）.
wustl.edu (Global: 3,160th place; Chinese: 4,093rd place)
medicine.wustl.edu
- Xie Y, Bowe B, Yan Y, Xian H, Li T, Al-Aly Z. Estimates of all cause mortality and cause specific mortality associated with proton pump inhibitors among US veterans: cohort study. BMJ (Washington University School of Medicine). May 2019, 365 [2025-12-28]. PMC 6538974 . PMID 31147311. doi:10.1136/bmj.l1580. （原始内容存档于2019-07-18）.
Taking PPIs is associated with a small excess of cause specific mortality including death due to cardiovascular disease, chronic kidney disease, and upper gastrointestinal cancer. The burden was also observed in patients without an indication for PPI use.
已忽略未知参数|article-number=(帮助); 温哥华格式错误 (帮助)
zenodo.org (Global: 621st place; Chinese: 1,608th place)
- Kia L, Kahrilas PJ. Therapy: Risks associated with chronic PPI use - signal or noise?. Nature Reviews. Gastroenterology & Hepatology. May 2016, 13 (5): 253–4 [2025-12-28]. PMID 27006255. S2CID 19207074. doi:10.1038/nrgastro.2016.44. （原始内容存档于2019-06-20）.